We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Development of High Throughput Assays for the Screening of Reversible and Mechanism-Based Cytochrome P450 Inhibition by Test Compounds


Assessment of cytochrome P450 (CYP450) inhibition is now performed early in drug development to decrease thelikelihood of progressing a compound with the potential to cause drug-drug interactions.

Screening for reversible CYP450inhibition, which is widely performed, does not have the ability to detect mechanism-based inhibition of CYP450 by test compounds.The prevalence, and clinical implications, of mechanism-based CYP450 inhibition has placed greater emphasis on the early detectionof compounds with this potential.

We have developed and validated a high throughput reversible CYP450 inhibition assay using humanliver microsomes and industry recommended probe substrates.